A practical reference on aggregation: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-09-09. Anything still debated is marked as such rather than presented as settled.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
| Property | Value | Notes |
|---|---|---|
| Molecular class | 31-amino-acid peptide | Modified glucagon-like peptide-1 analogue |
| Molecular mass | approximately 4114 Da | Calculated for the free peptide backbone |
| Appearance | white to off-white powder | Typical of purified lyophilised peptide batches |
| Solubility class | freely soluble in water | Aqueous solubility improves at slightly alkaline pH |
| Typical storage | -20 degrees Celsius, dry, dark | Protect from repeated freeze-thaw cycles |
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
As a peptide, semaglutide is sensitive to conditions that break amide bonds or modify side chains. Deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation are the main degradation routes described in published stability work. Rate depends strongly on pH, buffer species, ionic strength, temperature and exposure to light. Formulators therefore choose a defined solution pH and often add excipients such as phosphate buffer, propylene glycol and phenol, each of which plays a separate role in pH control, tonicity or preservation.
Storage guidance for the finished injectable product distinguishes the unused state from the in-use state. Before first use, pens are kept refrigerated between 2 and 8 degrees Celsius, protected from light, and never frozen, since freezing can disrupt the peptide or the device. After first use, label instructions in several markets permit storage at room temperature up to about 30 degrees Celsius for a limited number of days. Solid research-grade material is normally held at or below minus 20 degrees Celsius, often with desiccant, and allowed to equilibrate before opening.
Quantification and purity assessment rely on separation methods coupled to optical or mass detection. Reversed-phase high-performance liquid chromatography resolves the intact peptide from related impurities and is the standard assay technique. Size-exclusion chromatography measures aggregates, while ion-exchange chromatography separates charge variants produced by deamidation. Mass spectrometry confirms identity and detects mass shifts of a few daltons. In biological matrices, liquid chromatography with tandem mass spectrometry is often used because immunoassays can cross-react with endogenous GLP-1 or with circulating fragments.
== Pharmacology == CTAP is described as being a mu-selective opioid antagonist. In other words, when blocking opioid receptors, it is much more selective for the mu-opioid receptors than the other receptors. For example, in Norway rats, it has an IC50 value of 0.0021 μM at mu opioid 1 receptors, but has a value of 5.31 μM at delta opioid 1 receptors, which shows that it is much more selective for mu receptors, as can be seen by the smaller value. Additionally, it is able to cross the blood–brain barrier (BBB).
=== Primary amine biotinylation === The most common targets for modifying protein molecules are primary amine groups that are present as lysine side chain epsilon-amines and N-terminal α-amines. Amine-reactive biotinylation reagents can be divided into two groups based on water solubility. N-hydroxysuccinimide (NHS) esters have poor solubility in aqueous solutions. For reactions in aqueous solution, they must first be dissolved in an organic solvent, then diluted into the aqueous reaction mixture. The most commonly used organic solvents for this purpose are dimethyl sulfoxide (DMSO) and dimethyl formamide (DMF), which are compatible with most proteins at low concentrations. Because of the hydrophobicity of NHS-esters, NHS biotinylation reagents can also diffuse through the cell membrane, meaning that they will biotinylate both internal and external components of a cell.
Deoxyribozymes, also called DNAzymes or catalytic DNA, were first discovered in 1994. They are mostly single stranded DNA sequences isolated from a large pool of random DNA sequences through a combinatorial approach called in vitro selection or systematic evolution of ligands by exponential enrichment (SELEX). DNAzymes catalyze variety of chemical reactions including RNA-DNA cleavage, RNA-DNA ligation, amino acids phosphorylation-dephosphorylation, carbon-carbon bond formation, etc. DNAzymes can enhance catalytic rate of chemical reactions up to 100,000,000,000-fold over the uncatalyzed reaction. The most extensively studied class of DNAzymes is RNA-cleaving types which have been used to detect different metal ions and designing therapeutic agents. Several metal-specific DNAzymes have been reported including the GR-5 DNAzyme (lead-specific), the CA1-3 DNAzymes (copper-specific), the 39E DNAzyme (uranyl-specific) and the NaA43 DNAzyme (sodium-specific). The NaA43 DNAzyme, which is reported to be more than 10,000-fold selective for sodium over other metal ions, was used to make a real-time sodium sensor in cells.
Sources: en.wikipedia.org
DMT binds non-selectively with affinities below 0.6 μmol/L to the following serotonin receptors: 5-HT1A, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT6, and 5-HT7. An agonist action has been determined at 5-HT1A, 5-HT2A and 5-HT2C. Its efficacies at other serotonin receptors remain to be determined. Of special interest will be the determination of its efficacy at human 5-HT2B receptor as two in vitro assays evidenced DMT's high affinity for this receptor: 0.108 μmol/L and 0.184 μmol/L. This may be of importance because chronic or frequent uses of serotonergic drugs showing preferential high affinity and clear agonism at 5-HT2B receptor have been causally linked to valvular heart disease. It has also been shown to possess affinity for the dopamine D1, α1-adrenergic, α2-adrenergic, imidazoline-1, and σ1 receptors. Converging lines of evidence established activation of the σ1 receptor at concentrations of 50–100 μmol/L. Its efficacies at the other receptor binding sites are unclear. It has also been shown in vitro to be a substrate for the cell-surface serotonin transporter (SERT) expressed in human platelets, and the rat vesicular monoamine transporter 2 (VMAT2), which was transiently expressed in fall armyworm Sf9 cells. DMT inhibited SERT-mediated serotonin uptake into platelets at an average concentration of 4.00 ± 0.70 μmol/L and VMAT2-mediated serotonin uptake at an average concentration of 93 ± 6.8 μmol/L.
21 July The Bodyhunters, about the disappearance of Royal Marine Alan Addis; on 8 August 1980, Royal Marine went missing in North Arm; the Forensic Search Advisory Group, from the Home Office, was founded in 1988 by forensic archaeologist John Hunter of the University of Birmingham, with Sgt Mick Swindells of Lancashire Constabulary, providing the first evidence by an archaeologist in a British court; Swindells had found 5 yr old Rosie McCann, of Moorheys in Oldham, in only a few hours in March 1996, after she had disappeared on 14 January 1996 - the local police had been, conversely, searching for seven weeks and had not found anything in that time, and with the generous assistance of RAF search teams; the FSAG adopted a much different searching approach to typical police methods, with archaeology, more educated guesses, and applied geophysics; the individual was part of Naval Party 8901, to train locals in civil defence in 1980; Islands Radio; the team took ground-penetrating radar and five local policemen; three years previously detectives from Devon and Cornwall Police conducted an investigation and arrested four people - three of those were Titch Jaffray, Burnerd Peck and Tony Blake; the team were conducting a nine-day search in 1997; 80-90% of murders have disposal in known areas to the murderer; Chris Johnson was a former Royal Marine; the team looked in the cemetery first, with ground-penetrating radar, which could detect up to three metres below the surface, for irregularities; Tim Cotter, from the Royal Navy; the team knew that any disused buildings would be a plausible hiding place, as nothing is often suspected; in a search site, the team found mixed, or disturbed, soil. Narrated by Robin Ellis, made with the Discovery Channel 28 July Miracle Police, including the Audrey Santo case; personnel of the Roman Catholic Diocese of Worcester; the investigator Joe Nickell; Peter Gumpel of the Congregation for the Causes of Saints; evolutionary psychologist Robin Dunbar; John Polkinghorne of the University of Cambridge; Karen Armstrong, who wrote A History of God; the Lourdes Medical Bureau; Luigi Bommarito, Archbishop from 1988 to 2002 of the Roman Catholic Archdiocese of Catania. Narrated by Piers Gibbon, directed by Alexander Marengo, made by Ideal World with the Discovery Channel 4 August Dawn of the Death Ray, about the laser and its invention in July 1960; physicist Arthur Schawlow, inventor of the laser; testing of lasers took place at Kirtland Air Force Base, New Mexico, where an aircraft was first brought down with a laser in November 1973; a laser-equipped Boeing KC-135 was operated from 1973, by the 4900th Flight Test Group, led by Col John Otten, taking off in January 1975; fighter aircraft would launch air to air missiles, with insufficient fuel, at the aircraft, and the laser would attempt to shoot the missile down; after three years, on 26 May 1983, the laser shot down its first air to air Sidewinder missile; adverse atmospheric conditions often made an airborne laser ineffective; the White Sands Missile Range in New Mexico, and Leik Myrabo of the USAF Advanced Concepts Division; the 1991 Gulf War allowed much advanced technology to be fully evaluated - and Patriot missiles had mostly missed Iraqi Scud missiles; the Directed Energy Directorate of the Air Force Research Laboratory, and its Starfire Optical Range, and physicist Robert Fugate; John V. Breakwell; the USAF ordered seven airborne attack lasers, for delivery by 2008; Major-General Don Lamberson. Narrated by Michael Bywater, directed by Chris Durlacher, produced by David Dugan, made by Windfall Films 11 August Thin Air, about climbers on Mount Everest; in the 1996, eight participants on an Everest expedition died in one day; above 17,000 ft climbers experience weight loss and sleep loss; Peter Hackett (mountaineer); Ed Viesturs from Seattle; David Breashears, who made the documentary; when he was making a film in May 1996, eight climbers died in the 1996 Mount Everest disaster; climbers fly by helicopter to 9,000 ft, then climb to base camp at 17,600 ft; pulmonologist Brownie Schoene of the University of Washington School of Medicine in Seattle; psychologist Gail Rosenbaum; chronic mountain sickness and the portable hyperbaric bag, which is pumped to 2 PSI; the Khumbu Glacier and Khumbu Icefall; Guy Cotter of Adventure Consultants; the 'death zone' is above 26,000 ft; the Lhotse western face; the team reach the South Col, known as Camp VI; the Hillary Step; pulse oximetry and brain MRI scans are taken in Seattle. Broadcast on PBS as Everest - the death zone, when narrated by Jodie Foster. British edition narrated by Piers Gibbon, directed by David Breashears, made by Nova 18 August The Ten Plagues of Egypt, about the Plagues of Egypt in the Book of Exodus; Avi Weiss, who researched the Book of Exodus; doctor John S. Marr looked at the Ipuwer Papyrus, and worked with Curtis Malloy; marine biologist JoAnn Burkholder of North Carolina State University, and how Pfiesteria piscicida could be the first plague; Richard Wassersug of Dalhousie University in Canada, and a plague of frogs; entomologist Richard Brown of Mississippi State University in Starkville, Mississippi; public health entomologist Andrew Spielman of Harvard T.H. Chan School of Public Health; Roger Breeze of Plum Island Animal Disease Center; the final plague was likely caused by Stachybotrys chartarum, which made mycotoxin. Narrated by Jenni Murray, produced by Peter Spry-Leverton, directed by Bill Eagles, made by UFA GmbH and Café Productions, with The Learning Channel
== Structure == Cyclotides have a well-defined three-dimensional structure due to their interlocking disulfide bonds and cyclic peptide backbone. Backbone loops and selected residues are labeled on the structure to help orientation. The amino acid sequence (single-letter amino acid representation) for this peptide is indicated on the sequence diagram to the right. One of the interesting features of cyclic peptides is that knowledge of the peptide sequence does not reveal the ancestral head and tail; knowledge of the gene sequence is required for this. In the case of kalata B1 the indicated glycine (G) and asparagine (N) amino acids are the terminal residues that are linked in a peptide bond to cyclize the peptide.
== Interactions == Pindolol has been found to robustly potentiate the effects of the serotonergic psychedelic dimethyltryptamine (DMT). This is thought to be due to its serotonin 5-HT1A receptor antagonism, which is thought to disinhibit the effects of DMT.
Sources: en.wikipedia.org
=== Subcellular membrane fluidity under cold and osmotic stress === The efficiency of lactic acid bacteria cryopreservation is not consistent and may lead to cell death. Lactobacillus delbrueckii subsp. bulgaricus has adapted to defend against cold stress. The way most cells react to the cold is by changing the fluidity of the cellular membrane, but this particular bacterium has acquired different tactics to fight against cold stress. The first way to cope with the cold is to increase viscosity by taking in compounds such as disaccharides, polysaccharides, amino acids and antioxidants. The second strategy used is performed by inducing active responses during the fermentation or post-fermentation processes. By modifying these it will change the temperature, pH and medium composition. This results in specific metabolic pathways becoming active, with the synthesis of cold shock proteins.
Each country has its own laws and regulations for the import and export of goods into and out of a country, which its customs authority enforces. The import or export of certain goods may be restricted or prohibited, in which case customs controls enforce these policies. Customs enforcement at borders can also entail collecting excise tax and preventing the smuggling of dangerous or illegal goods. A customs duty is a tariff or tax on the importation (usually) or exportation (unusually) of goods. In many countries, border controls for arriving passengers at many international airports and some road crossings are separated into red and green channels to prioritise customs enforcement. Within the European Union's common customs area, airports may operate additional blue channels for passengers arriving from within that area. For such passengers, border control may focus specifically on prohibited items and other goods that are not covered by the common policy. Luggage tags for checked luggage travelling within the EU are green-edged to facilitate identification. In most EU member states, travellers coming from other EU countries within the Schengen Area can use the green lane. However, airports outside the Schengen Area, or those with frequent flights arriving from jurisdictions within the Schengen Area but outside the European Union, may use blue channels for convenience and efficiency. A customs area is a designated area for storing commercial goods that have not cleared border controls.
phagocytosis The process by which foreign cells, molecules, and small particulate matter are engulfed and ingested via endocytosis by specialized cells known as phagocytes (a class which includes macrophages and neutrophils).
Sources: en.wikipedia.org
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.
No. It shares high sequence identity but carries non-natural modifications that alter its stability and clearance. The naturally occurring hormone is broken down within minutes, while the synthetic analogue circulates far longer.
Attachment to serum albumin reduces renal filtration of the peptide and shields it from enzymatic breakdown. The consequence is a much longer interval between administrations than unmodified peptides allow. The precise contribution of binding affinity to overall duration is still being quantified.
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.